10 Best Dialysis and Kidney Disease Stocks to Buy

Published on October 25, 2023 at 4:15 am by Syed Ijaz in Hedge Funds, News

In this article, we will take a look at the 10 best dialysis and kidney disease stocks to buy. To see more such companies, go directly to 5 Best Dialysis and Kidney Disease Stocks to Buy.

According to the National Kidney Foundation, millions of people die every year due to kidney failures because they do not receive affordable treatment. The Global Burden of Disease, which provides comprehensive detail on mortality and disability throughout countries, stated that in 2017, around 1.2 million people died because of chronic kidney failures. The study also described that since 1990, the percentage of people needing dialysis has jumped to 40% as of 2020. The foundation also analyzed that China will lose approximately $558 billion through the next decade due to impacts on death and disability because of heart failure and kidney disease. In the US alone, the need for kidney organ donors is estimated to rise 8% annually from 2018. And by the year of 2040, chronic kidney disease is set to be the 5^th global reason of deaths.

The International Society of Nephrology, an international organization dedicated to enhancing global kidney health, said that in 2023, roughly 850 million people around the world are suffering from chronic kidney disease. In many nations, kidney failure treatments or dialysis are not publicly financed. Dialysis usually has two types: hemodialysis and peritoneal dialysis. Dialysis costs more than $25,000 per year, according to the International Society of Nephrology.

“Chronic kidney disease has emerged as one of the leading causes of mortality worldwide, and it is one of a small number of non-communicable diseases that have shown an increase in associated deaths over the past 2 decades,” according to the US National Institute of Health’s National Library of Medicine.

Healthcare organizations have been investing in kidney and dialysis treatments over the years. Some of the notable names in the dialysis industry are Thermo Fisher Scientific Inc. (NYSE:TMO), Merck & Co., Inc. (NYSE:MRK), The Cigna Group (NYSE:CI), and others.

Kidney diseases are expected to gradually rise overtime and firms have been allocating their capital spending towards technological advancements for the treatment of chronic kidney diseases and dialysis. We decided to take a look at some of the best dialysis and kidney disease stocks to buy in the healthcare sector. Some other major stocks that will appear later in our article are Humana Inc. (NYSE:HUM), Boston Scientific Corporation (NYSE:BSX), Bristol-Myers Squibb Company (NYSE:BMY), and others. You can also read 12 Best Health Insurance Stocks to Buy and 12 Cheap Healthcare Stocks to Buy in 2023 for even more healthcare stocks.

Looking ahead, the wearable artificial kidney and implantable bioartificial kidney each have a potential to be the leading treatment for chronic kidney diseases and dialysis.

“They are expected to contribute to higher toxin clearance with more cardiovascular stability as well as improved quality of life,” the National Library of Medicine reported. In the US alone, there are roughly 750,000 patients suffering from end-stage renal disease, while 2.6 million people receive renal replacement therapy around the world.

In 2022, the end stage renal disease sector was valued at around $114 billion and it is expected to reach more than $183.9 billion by 2032, according to Global Market Insights. In September 2023, 17 patient advocacy organizations created the Global Patient Alliance for Kidney Health to form policies that enhance reach to screening and early treatment of chronic kidney disease, Bloomberg reported.

Photo by martha-dominguez-de-gouveia on Unsplash

Pharmaceutical companies globally are carrying out trials on kidney diseases’ treatments. The Wall Street Journal reported that Novo Nordisk A/S (NYSE:NVO)’s Ozempic drug demonstrated success in its trial for kidney failure in patients suffering from diabetes. In terms of global revenue in the kidney and dialysis sector, North America had the highest revenue share of 42% in 2022, while Europe is poised to grow at a revenue share of 23.7% from 2023-2032. In products category, the hemodialysis equipment segment had a market share of 32% with leading the market and is rising at the highest compound annual growth rate from 2023 to 2032. The dialysis centers & hospitals segment maintained the highest share in end-users. IBIS World reported that dialysis centers in the US generated revenue of about $36 billion this year which jumped at a compound annual growth rate of 2.4% over the last five years.

Our Methodology

Following a thorough analysis of the healthcare and pharmaceutical sectors, we compiled our list of the best dialysis and kidney disease stocks to buy and filtered the companies that had a notable presence in the dialysis and kidney disease sector. We then picked the top 30 kidney disease and dialysis stocks and then ranked them according to their market capitalization with more than $65 billion. The hedge fund sentiment for each stock was extracted from Insider Monkey’s database as of second quarter of 2023, encompassing 910 top-tier hedge funds. We then ranked the stocks in ascending order of the number of hedge fund investors.

Best Dialysis and Kidney Disease Stocks to Buy

10. Becton, Dickinson and Company (NYSE:BDX)

Number of Hedge Fund Holders In Q2 2023: 55

Market Capitalization: $75.6 Billion

Founded in 1897 and headquartered in New Jersey, Becton, Dickinson and Company (NYSE:BDX) ranks 10th in our list of the best dialysis and kidney disease stocks to buy. With a market capitalization of $75.6 billion, Becton, Dickinson and Company (NYSE:BDX) provides comprehensive plans for creating, restoring, and retaining the patients’ arteriovenous. Arteriovenous is termed as a lifeline for hemodialysis patients. Becton, Dickinson and Company (NYSE:BDX) also recently received clearance for its Aspirex mechanical aspiration thrombectomy system to eliminate acute emboli and thrombi for hemodialysis access of arteriovenous grafts. It posted fiscal Q3 EPS of $2.96 that came ahead of analysts’ forecast of $2.89.

During Q2 2023, 55 out of the 910 hedge funds part of Insider Monkey’s database had held a stake in Becton, Dickinson and Company (NYSE:BDX). Out of these, the firm’s largest shareholder is David Blood and Al Gore’s Generation Investment Management since it owns 1.9 million shares that are worth $501.8 million.

Becton, Dickinson and Company (NYSE:BDX) joins The Cigna Group (NYSE:CI), Merck & Co., Inc. (NYSE:MRK), and Thermo Fisher Scientific Inc. (NYSE:TMO) in our list of the best dialysis and kidney disease stocks to buy.

9. Abbott Laboratories (NYSE:ABT)

Number of Hedge Fund Holders In Q2 2023: 62

Market Capitalization: $160.4 Billion

Founded in 1888 and headquartered in Illinois, Abbott Laboratories (NYSE:ABT) ranks 9th in our list of the best dialysis and kidney disease stocks to buy. With a market capitalization of $160.4 billion, Abbott Laboratories (NYSE:ABT) provides therapeutic nutrition for patients on dialysis stage 5 of chronic kidney disease. The company reported second quarter EPS of $1.08 that beat analysts’ expectations of $1.05.

As of June 2023, 62 out of the 910 hedge funds part of Insider Monkey’s research were Abbott Laboratories (NYSE:ABT)’s investors. Ric Dillon’s Diamond Hill Capital is the largest shareholder among these because of its $553 million stake.

8. Medtronic plc (NYSE:MDT)

Number of Hedge Fund Holders In Q2 2023: 63

Market Capitalization: $96.2 Billion

Medtronic plc (NYSE:MDT) is an Ireland-based company which was incorporated in 1949. With a market capitalization of $96.2 billion, Medtronic plc (NYSE:MDT) recently collaborated with DaVita Inc. (NYSE: DVA) to launch Mozarc Medical, an independent new firm to enhance kidney health and patient-centered technology solutions. It posted a 6% revenue growth in fiscal Q1 and EPS of $0.593.

During 2023’s second quarter, 63 out of the 910 hedge funds part of Insider Monkey’s research had invested in Medtronic plc (NYSE:MDT). Jean-Marie Eveillard’s First Eagle Investment Management is the firm’s biggest shareholder through a $484 million stake that comes with 5.5 million shares.

7. HCA Healthcare, Inc. (NYSE:HCA)

Number of Hedge Fund Holders In Q2 2023: 66

Market Capitalization: $65.2 Billion

HCA Healthcare, Inc. (NYSE:HCA) provides healthcare service across the US. Founded in 1968 and is headquartered in Nashville, Tennessee, HCA Healthcare, Inc. (NYSE:HCA) ranks 7th in our list of the best dialysis and kidney disease stocks to buy. The company provides treatment plans for patients suffering from renal failure. HCA Healthcare, Inc. (NYSE:HCA) is the first company in Florida to carry out robotic live kidney donation and are approved by the United Network of Organ Sharing for kidney and liver transplantation. It posted Q2 consolidated revenue of $15.9 billion, up 7% from a year earlier and EPS of $4.21.

66 out of the 910 hedge funds researched by Insider Monkey had invested in the firm as of Q2 2023. HCA Healthcare, Inc. (NYSE:HCA)’s largest hedge fund investor is Jean-Marie Eveillard’s First Eagle Investment Management since it owns 4.6 million shares that are worth $1.4 billion.

6. Bristol-Myers Squibb Company (NYSE:BMY)

Number of Hedge Fund Holders In Q2 2023: 66

Market Capitalization: $119.8 Billion

Founded in 1887 and headquartered in New York, Bristol-Myers Squibb Company (NYSE:BMY) provides different treatment plans for kidney failures including hemodialysis and peritoneal dialysis. With a market capitalization of around $120 billion, Bristol-Myers Squibb Company (NYSE:BMY) ranks 6th in our list of the best dialysis and kidney disease stocks to buy. In the second quarter, it reported EPS of $1.93 and revenue of $154 million.

By the end of this year’s second quarter, 66 out of the 910 hedge funds part of Insider Monkey’s research were Bristol-Myers Squibb Company (NYSE:BMY)’s investors. Richard S. Pzena’s Pzena Investment Management is the largest shareholder among these since it owns 4.3 million shares that are worth $277 million.

Along with The Cigna Group (NYSE:CI), Merck & Co., Inc. (NYSE:MRK), and Thermo Fisher Scientific Inc. (NYSE:TMO), Bristol-Myers Squibb Company (NYSE:BMY) is one of the top dialysis and kidney disease stocks to buy according to hedge funds.

Click to continue reading and see 5 Best Dialysis and Kidney Disease Stocks to Buy.

AI Fire Sale: Insider Monkey’s #1 AI Stock Pick Is On A Steep Discount

Published on May 1, 2024 at by Inan Dogan, PhD

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

The whispers are turning into roars.

Artificial intelligence isn’t science fiction anymore.

It’s the revolution reshaping every industry on the planet.

From driverless cars to medical breakthroughs, AI is on the cusp of a global explosion, and savvy investors stand to reap the rewards.

Here’s why this is the prime moment to jump on the AI bandwagon:

Exponential Growth on the Horizon: Forget linear growth – AI is poised for a hockey stick trajectory.

Imagine every sector, from healthcare to finance, infused with superhuman intelligence.

We’re talking disease prediction, hyper-personalized marketing, and automated logistics that streamline everything.

This isn’t a maybe – it’s an inevitability.

Early investors will be the ones positioned to ride the wave of this technological tsunami.

Ground Floor Opportunity: Remember the early days of the internet?

Those who saw the potential of tech giants back then are sitting pretty today.

AI is at a similar inflection point.

We’re not talking about established players – we’re talking about nimble startups with groundbreaking ideas and the potential to become the next Google or Amazon.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 10,000% Return: This AI Stock is a Diamond in the Rough (But Our Help is Key!)

The AI revolution is upon us, and savvy investors stand to make a fortune.

But with so many choices, how do you find the hidden gem – the company poised for explosive growth?

That’s where our expertise comes in.

We’ve got the answer, but there’s a twist…

Imagine an AI company so groundbreaking, so far ahead of the curve, that even if its stock price quadrupled today, it would still be considered ridiculously cheap.

That’s the potential you’re looking at. This isn’t just about a decent return – we’re talking about a 10,000% gain over the next decade!

Our research team has identified a hidden gem – an AI company with cutting-edge technology, massive potential, and a current stock price that screams opportunity.

This company boasts the most advanced technology in the AI sector, putting them leagues ahead of competitors.

It’s like having a race car on a go-kart track.

They have a strong possibility of cornering entire markets, becoming the undisputed leader in their field.

Here’s the catch (it’s a good one): To uncover this sleeping giant, you’ll need our exclusive intel.

We want to make sure none of our valued readers miss out on this groundbreaking opportunity!

That’s why we’re slashing the price of our Premium Readership Newsletter by a whopping 75%.

For a ridiculously low price of just $24, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single restaurant meal!

Here’s why this is a deal you can’t afford to pass up:

The Name of the Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential.
Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.
Lifetime Money-Back Guarantee: If you’re not absolutely satisfied with our service, we’ll provide a full refund ANYTIME, no questions asked.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

Head over to our website and subscribe to our Premium Readership Newsletter for just $24.
Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.
Sit back, relax, and know that you’re backed by our ironclad lifetime money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Subscribe Now!

A New Dawn is Coming to U.S. Stocks

Published on May 2, 2024 at by Insider Monkey Staff

I work for one of the largest independent financial publishers in the world – representing over 1 million people in 148 countries.

We’re independently funding today’s broadcast to address something on the mind of every investor in America right now…

Should I put my money in Artificial Intelligence?

Here to answer that for us… and give away his No. 1 free AI recommendation… is 50-year Wall Street titan, Marc Chaikin.

Marc’s been a trader, stockbroker, and analyst. He was the head of the options department at a major brokerage firm and is a sought-after expert for CNBC, Fox Business, Barron’s, and Yahoo! Finance…

But what Marc’s most known for is his award-winning stock-rating system. Which determines whether a stock could shoot sky-high in the next three to six months… or come crashing down.

That’s why Marc’s work appears in every Bloomberg and Reuters terminal on the planet…

And is still used by hundreds of banks, hedge funds, and brokerages to track the billions of dollars flowing in and out of stocks each day.

He’s used this system to survive nine bear markets… create three new indices for the Nasdaq… and even predict the brutal bear market of 2022, 90 days in advance.

Click to continue reading…

Insider Monkey Ads

Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Log In

Sign Up